Skip to main content

Table 4 Incidence of adverse events

From: Evaluation of the irritable bowel syndrome severity index in Japanese male patients with irritable bowel syndrome with diarrhea

Event

Placebo

Ramosetron 5 μg

(n = 51)

(n = 47)

All adverse events

20 (39.2%)

27 (57.4%)

Gastrointestinal disorders

8 (15.7%)

13 (27.7%)

 Abdominal discomfort

0 (0.0%)

2 (4.3%)

 Constipation

2 (3.9%)

0 (0.0%)

 Hard stool

3 (5.9%)

9 (19.1%)

 Nausea

2 (3.9%)

0 (0.0%)

Infections and infestations

4 (7.8%)

5 (10.6%)

 Nasopharyngitis

4 (7.8%)

3 (6.4%)

 Gastroenteritis

0 (0.0%)

2 (4.3%)

Hepatobiliary disorders

2 (3.9%)

2 (4.3%)

 Hepatic function abnormal

2 (3.9%)

1 (2.1%)

Skin and subcutaneous tissue disorder

2 (3.9%)

3 (6.4%)

 Dermatitis contact

1 (2.0%)

2 (4.3%)

  1. Data are expressed as number (%). Events with an incidence of ≥ 3% in any of the groups are listed